RxDoctor Payments Data

Troy Duncan

Psychiatric/Mental Health · Greensboro, NCNPI 1568989465

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 23 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 7 manufacturers reported payments, led by Lundbeck LLC at 32.7% of the total. 2025 is the largest year on record at $216, 6.8 times the $32 reported in 2023. That places this record below the midpoint for psychiatric/mental health clinicians in NC, where the typical reported total is $449.

$436in general payments, 2019–2025

Across 23 payments — averaging $18.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lundbeck LLC$142
  • AbbVie$74
  • E.r. Squibb & Sons, L.L.C.$63
  • Johnson & Johnson$57
  • Neurocrine Biosciences, Inc.$36
  • Otsuka America Pharmaceutical, Inc.$34
  • plus $29 from 1 others

What the payments were for

  • Food & beverage$436100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$436 in reported general payments places this provider in the 45th percentile of 947 psychiatric/mental health providers in North Carolina.

See all psychiatric/mental health providers in North Carolina

Medicare billing

Part B allowed, 2024
$1,251
Medicare patients
14
Services billed
24

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega TrinzaPaliperidone Palmitate11$115,919
Invega SustennaPaliperidone Palmitate33$89,744
VraylarCariprazine Hcl16$25,000
Clozapine OdtClozapine18$6,770
Olanzapine132$6,195
Risperidone OdtRisperidone19$3,905
Divalproex Sodium125$3,903
Fluphenazine Hcl17$3,443
Clozapine29$2,700
Duloxetine Hcl58$2,265
Paliperidone ErPaliperidone11$2,220
Carbamazepine ErCarbamazepine12$2,120
Aripiprazole48$1,959
Divalproex Sodium ErDivalproex Sodium26$1,518
Buspirone Hcl102$1,375

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Trinza, Invega Sustenna$57$205,66344 claims
AbbVieVraylar$74$25,00016 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 947 psychiatric/mental health providers in North Carolina.

Other psychiatric/mental health in Greensboro

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →